NEW YORK (Reuters) – Allergan Plc on Wednesday said it plans to cut over 1,000 jobs and eliminate an additional 400 currently open positions, as it works to cut costs in the face of new competition for its second most important drug, dry-eye treatment Restasis.
Powered by WPeMatico